Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recordati SpA (REC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9919
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and analgesia and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over the counter (OTC) and non-prescription pharmaceuticals, antiinfectives and others. It also produces pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs) and intermediates. Recordati sells its pharmaceuticals directly in the countries where it is present and through licensees in other places. Recordati is headquartered in Milano, Italy.

Recordati SpA (REC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati SpA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
Private Equity 23
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Partnerships 25
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Licensing Agreements 28
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique – Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Acquisition 39
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA – Key Competitors 46
Recordati SpA – Key Employees 47
Recordati SpA – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 51
Financial Announcements 51
Oct 30, 2018: Recordati announces sales and margin growth in the first nine months 2018. revenues +5.1%, ebitda +11.1%, operating income +9.6%,  net income +8.2%. interim dividend € 0.45 (+7.1%). 51
Jul 26, 2018: Recordati announces sales and margin growth in the first half 2018. Revenues +6.9%, operating income +14.1%, net income +11.7% 52
May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018 53
Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts 54
Feb 08, 2018: Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6% 57
Oct 26, 2017: Recordati: Very Good Results in the First Nine Months 2017. Continued Growth in Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend € 0.42 (+20%) 58
Jul 27, 2017: Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8% 60
May 04, 2017: Recordati: Excellent Results in the First Quarter 2017. Continued Growth in Sales +13.1%, Operating Income +19.0%, Net Income +19.9% 62
Mar 01, 2017: Recordati: Board Approves The 2016 Accounts. Sales € 1,153.9 Million (+10.1%), Operating Income € 327.4 Million (+17.6%) And Net Income € 237.4 Million (+19.4%). 2016 Dividend € 0.70 (+16.7%) 63
Feb 09, 2017: Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Recordati SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique - Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA, Key Competitors 46
Recordati SpA, Key Employees 47
Recordati SpA, Subsidiaries 48

List of Figures
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kathmandu Holdings Limited:企業の戦略・SWOT・財務分析
    Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Kathmandu Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ferroglobe PLC (GSM):企業の財務・戦略的SWOT分析
    Ferroglobe PLC (GSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sabre Corporation:企業の戦略・SWOT・財務分析
    Sabre Corporation - Strategy, SWOT and Corporate Finance Report Summary Sabre Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • WGL Holdings Inc (WGL)-石油・ガス分野:企業M&A・提携分析
    Summary WGL Holdings, Inc. (WGL) is an energy holding company that delivers natural gas, and provides energy-related products and services to customers. It also provides design-build energy efficient and sustainable solutions and water and energy-related infrastructure services. The company delivers …
  • Energisa SA (ENGI11):企業の財務・戦略的SWOT分析
    Energisa SA (ENGI11) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Australia and New Zealand Banking Group Ltd:企業のM&A・事業提携・投資動向
    Australia and New Zealand Banking Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Australia and New Zealand Banking Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • SINTX Technologies Inc (SINT):企業の財務・戦略的SWOT分析
    SINTX Technologies Inc (SINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • KBR Inc (KBR):企業の財務・戦略的SWOT分析
    KBR Inc (KBR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Chiba University:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiba University (Chiba) is an educational university that offers undergraduate education, short-term study program, graduation, double degree program, global COE program, good practice program, distinctive education and research, and international collaborative research program. The univers …
  • Sodra Skogsagarna ekonomisk forening:企業の戦略的SWOT分析
    Sodra Skogsagarna ekonomisk forening - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Akamai Technologies Inc (AKAM):企業の財務・戦略的SWOT分析
    Akamai Technologies Inc (AKAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA):企業の財務・戦略的SWOT分析
    Gammon Infrastructure Projects Ltd (GAMMNINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Krispy Kreme Doughnuts, Inc.:企業の戦略的SWOT分析
    Krispy Kreme Doughnuts, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Century Aluminum Co:企業の戦略・SWOT・財務情報
    Century Aluminum Co - Strategy, SWOT and Corporate Finance Report Summary Century Aluminum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ultra Petroleum Corp (UPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas reserves in the Green River Basin of Wyoming, the Pinedale and Jonah fields, and oil reserves in the U …
  • Cremonini S.p.A. (Foodservice):企業の戦略・SWOT・財務情報
    Cremonini S.p.A. (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Cremonini S.p.A. (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Enusa Industrias Avanzadas, S.A., S.M.E:企業の戦略的SWOT分析
    Enusa Industrias Avanzadas, S.A., S.M.E - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • AmerisourceBergen Corp (ABC):医療機器:M&Aディール及び事業提携情報
    Summary AmerisourceBergen Corp (AmerisourceBergen) is a pharmaceutical sourcing and distribution services company. It offers a wide range of services ranging from drug distribution to manufacturer solutions including niche premium logistics services, reimbursement and pharmaceutical consulting servi …
  • Composites Horizons, Inc.:企業の戦略・SWOT・財務分析
    Composites Horizons, Inc. - Strategy, SWOT and Corporate Finance Report Summary Composites Horizons, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Chubu Electric Power Co Inc (9502)-石油・ガス分野:企業M&A・提携分析
    Summary Chubu Electric Power Co Inc (Chubu) is an energy utility. It generates and procures electricity; and offers electric network related services. The company produces electricity from nuclear, hydro, solar, biomass, wind, coal, fuel oil, and natural gas sources. Chubu has interests in upstream …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆